Organovo wins innovation award for 3D bioprinter

By Dylan Bushell-Embling
Monday, 28 November, 2011

American start-up Organovo and its Australian partner Invetech have won a state-sponsored innovation award after developing the world's first commercial 3D bioprinter.

Organovo and electronics and engineering firm Inventech received one of 12 plaudits handed out at the 2011 Australian Engineering Excellence Awards in Canberra last week.

The companies received the Engineering Innovation Award for their work developing the NovoGen MMX bioprinter, a hardware and software platform for shaping human cells into 3D tissue.

Organovo claims the output tissue is superior even to animal models for research into drug discovery.

Another goal of the emerging 3D bioprinting field is to one day be able to construct full organs from a recipients' own biotissue.

Announcing the award, Senator Kim Carr said the product represents a major medical breakthrough. “For decades the goal of tissue engineers has been to advance beyond simple cell cultures to creating three-dimensional organs,” he said.

“This partnership took just nine months to solve these engineering challenges and design, develop, manufacture and ship the world’s first commercial 3D bioprinter.”

The Engineering Innovation Award is sponsored by the Australian government's AusIndustry. The criteria for winning is a project's potential contribution to the Australian economy.

The Engineering Excellence Awards is Engineers Australia's gala event. Other winners at this year's ceremony include CAT Projects, CEA Technologies and Finisar Australia.

Related News

Common arthritis drug also lowers blood pressure

Scientists have known for a while that methotrexate helps with inflammation, but it may also help...

AI enables precise gene editing

A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...

Shingles vaccine may reduce risk of heart attack and stroke 

Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd